IRLAB Therapeutics AB (publ) Total Liabilities
IRLAB Therapeutics AB (publ) total liabilities. Based on the latest financial reports, IRLAB Therapeutics AB (publ) (IRLAB-A) has total liabilities worth Skr107.49 Million SEK (≈ $11.57 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check IRLAB Therapeutics AB (publ) liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of IRLAB Therapeutics AB (publ) (2013–2025)
Total liabilities of IRLAB Therapeutics AB (publ) from 2013 to 2025. This chart illustrates how IRLAB Therapeutics AB (publ)'s total liabilities have evolved over time, based on quarterly financial data.
IRLAB Therapeutics AB (publ) Competitors by Total Liabilities
The table below lists competitors of IRLAB Therapeutics AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CHARBONE HYDROGEN CORP.
F:K47
|
Germany | €10.91 Million |
|
Smart Concrete Public Company Limited
BK:SMART
|
Thailand | ฿95.74 Million |
|
Jericho Oil Corp
V:JEV
|
Canada | CA$5.98 Million |
|
Logah Technology Corp
TW:3593
|
Taiwan | NT$929.82 Million |
|
Przedsiebiorstwo Przemyslu Spozywczego PEPEES S.A.
WAR:PPS
|
Poland | zł181.95 Million |
|
Bintang Mitra Semestaraya Tbk
JK:BMSR
|
Indonesia | Rp767.75 Billion |
|
JERICHO OIL
F:JLM
|
Germany | €5.25 Million |
|
BonTerra Resources Inc
V:BTR
|
Canada | CA$33.33 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down IRLAB Therapeutics AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is IRLAB Therapeutics AB (publ)'s balance sheet.
Liquidity & Leverage Metrics
IRLAB Therapeutics AB (publ) Total Liabilities Ratios Explained
IRLAB Therapeutics AB (publ) total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.80 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.76 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.50 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.78 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how IRLAB Therapeutics AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for IRLAB Therapeutics AB (publ) (2013–2025)
The table below shows the annual total liabilities of IRLAB Therapeutics AB (publ) from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr107.49 Million ≈ $11.57 Million |
+3.78% |
| 2024-12-31 | Skr103.58 Million ≈ $11.15 Million |
+68.81% |
| 2023-12-31 | Skr61.36 Million ≈ $6.60 Million |
+87.50% |
| 2022-12-31 | Skr32.72 Million ≈ $3.52 Million |
-55.15% |
| 2021-12-31 | Skr72.97 Million ≈ $7.85 Million |
+228.86% |
| 2020-12-31 | Skr22.19 Million ≈ $2.39 Million |
-15.44% |
| 2019-12-31 | Skr26.24 Million ≈ $2.82 Million |
+110.59% |
| 2018-12-31 | Skr12.46 Million ≈ $1.34 Million |
+56.32% |
| 2017-12-31 | Skr7.97 Million ≈ $857.81K |
-13.57% |
| 2016-12-31 | Skr9.22 Million ≈ $992.54K |
+1.74% |
| 2015-12-31 | Skr9.06 Million ≈ $975.54K |
-49.23% |
| 2014-12-31 | Skr17.86 Million ≈ $1.92 Million |
+254971.43% |
| 2013-12-31 | Skr7.00K ≈ $753.31 |
-- |
About IRLAB Therapeutics AB (publ)
IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson's disease and other central nervous system (CNS) disorders in the United States. The company develops Mesdopetam (IRL790), which has completed both a Phase IIb clinical trial for the treatment of levodopa-induced dyskinesias, and a Phase I clinical trial for the treatment of Parkinson's disease psychosis; Pir… Read more